Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.86 USD | +4.27% | +11.87% | +54.20% |
Apr. 23 | Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU | MT |
Apr. 22 | RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.20% | 1.51B | |
+1.63% | 42.75B | |
+47.70% | 41.61B | |
+12.02% | 41.34B | |
-8.83% | 26.59B | |
+6.46% | 25.49B | |
-23.37% | 18.12B | |
+30.02% | 12.24B | |
-2.44% | 11.76B | |
+7.94% | 11B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Edgewise Therapeutics Drug Candidate to Treat Duchenne Gets FDA's Fast Track Designation